Vista Cima Wealth Management LLC Buys Shares of 5,061 Merck & Co., Inc. $MRK

Vista Cima Wealth Management LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,061 shares of the company’s stock, valued at approximately $425,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MRK. Brighton Jones LLC increased its stake in Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after purchasing an additional 8,710 shares during the period. Sivia Capital Partners LLC grew its holdings in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares during the last quarter. Good Life Advisors LLC increased its stake in Merck & Co., Inc. by 35.9% in the 2nd quarter. Good Life Advisors LLC now owns 15,663 shares of the company’s stock worth $1,240,000 after buying an additional 4,141 shares during the period. Oak Harvest Investment Services lifted its holdings in Merck & Co., Inc. by 7.7% during the 2nd quarter. Oak Harvest Investment Services now owns 58,922 shares of the company’s stock valued at $4,664,000 after buying an additional 4,194 shares in the last quarter. Finally, Donoghue Forlines LLC lifted its holdings in Merck & Co., Inc. by 17.7% during the 2nd quarter. Donoghue Forlines LLC now owns 18,341 shares of the company’s stock valued at $1,452,000 after buying an additional 2,755 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MRK shares. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $82.00 to $130.00 in a research report on Thursday, December 18th. Morgan Stanley boosted their price target on Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Royal Bank Of Canada started coverage on Merck & Co., Inc. in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 price objective on the stock. Scotiabank lifted their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a research report on Thursday, December 4th. Finally, Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price for the company in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $126.81.

Merck & Co., Inc. Trading Down 0.3%

NYSE MRK opened at $115.61 on Friday. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The company has a market capitalization of $285.84 billion, a price-to-earnings ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27. The company’s 50-day simple moving average is $115.26 and its two-hundred day simple moving average is $99.58.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 46.70%.

Insider Buying and Selling

In other news, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the sale, the chief marketing officer directly owned 80,615 shares in the company, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares in the company, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 320,176 shares of company stock valued at $38,281,735 over the last three months. Corporate insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.